Abstract | The identification of modifiable risk factors for the development of rheumatic conditions and their sequelae is crucial for reducing the substantial worldwide burden of these diseases. However, the validity of such research can be threatened by sources of bias, including confounding, measurement and selection biases. In this Review, we discuss potentially major issues of selection bias-a type of bias frequently overshadowed by other bias and feasibility issues, despite being equally or more problematic-in key areas of rheumatic disease research. We present index event bias (a type of selection bias) as one of the potentially unifying reasons behind some unexpected findings, such as the 'risk factor paradox'-a phenomenon exemplified by the discrepant effects of certain risk factors on the development versus the progression of osteoarthritis (OA) or rheumatoid arthritis (RA). We also discuss potential selection biases owing to differential loss to follow-up in RA and OA research, as well as those due to the depletion of susceptibles (prevalent user bias) and immortal time bias. The lesson remains that selection bias can be ubiquitous and, therefore, has the potential to lead the field astray. Thus, we conclude with suggestions to help investigators avoid such issues and limit the impact on future rheumatology research.
Introduction
Rheumatic and musculoskeletal conditions, and their sequelae, constitute a tremendous disease burden world wide. Unbiased research that accurately and reliably determines modifiable risk factors for the development of rheumatic conditions and their sequelae is critical to reduce this burden. Among the major sources of bias that threaten the validity of research findings, confounding and measurement biases have generally received their due attention from investigators and clinicians. How ever, selection bias, which tends to be insidious (yet equally or more problematic), is frequently overshadowed by other bias and feasibility issues. In this article, we review poten tially major selection bias issues in key areas of rheumatic disease research. As most of these issues are not unique to rheumatic conditions, we also describe notable exam ples from nonrheumatic conditions to help crystallize our discussions.
Disease burden of arthritic conditions
In the US alone, arthritis affected approximately 43 million people in 1997 and is projected to affect 60 million people by 2020. 1 The burden of disease involves not only the morbidity from arthritis, but also its associated comor bidities, sequelae events, and premature mortality. For example, osteoarthritis (OA), the most common joint dis order among adults in the US, causes pain and decreased mobility, and OA progres sion leads to disability, joint failure, and total joint replacement. Rheumatoid arthri tis (RA), a chronic and systemic inflammatory condition, leads to joint pain and deformity, as well as premature cardiovascular events and mortality. Sequelae events of these conditions play a major part in the disease burden among affected indivi duals, as well as in the burden to society in general; thus, these complications represent a compelling target for secondary or tertiary preven tion. Our ability to prevent these potentially debilitat ing and costly disease sequelae depends on an accurate understanding of modifiable risk factors for these events. Ultimately, unbiased determination of risk factors for disease progression or sequelae events holds the promise of improving our ability to prevent these outcomes through risk factor modification in clinical care and public health practice.
The risk factor paradox
In rheumatic diseases Despite substantial research progress over the past few decades enhancing our knowledge of the risk factors for the incidence of musculoskeletal conditions (for primary prevention), evidence regarding the risk factors for disease progression or sequelae events among indivi duals with musculoskeletal conditions (for secondary or tertiary prevention) has often been inconsistent, or some times even paradoxical (Table 1) . [2] [3] [4] [5] [6] For example, over the past few decades, a number of risk factors for inci dent knee OA have been consistently identified, includ ing female sex, obesity, high bone mineral density, knee injury, repetitive occupational stress on joints, and certain sports. 7, 8 By contrast, a systematic review of 36 articles concluded that sex, knee pain, radiological severity, joint injury, quadriceps strength, and regular sport activi ties are not associated with the risk of OA progression. association even between obesity or ageing (two well established risk factors) and the risk of knee OA progres sion. 9 Interestingly, high bone mineral density (another risk factor for the development of OA) was associated with a reduced risk of radiographic OA progression. [10] [11] [12] [13] Similarly, while smoking is a wellestablished risk factor for the development of incident RA, several cohort studies have found that smoking has an inverse or null associ ation with radiological RA progression (the 'smoking paradox'). [14] [15] [16] For example, a study based on a prospective early RA cohort (n = 813) reported that current smokers had a 50% lower risk of structural disease progression compared with nonsmokers (multi variate odds ratio 0.50, 95% CI 0.27-0.93).
14 Another RA cohort study (n = 2004) found that smoking intensity is associated with an inverse doseresponse (P <0.001); heavy smokers pro gressed significantly less than moderate smokers or non smokers (average progression of the maximum damage score, 1.21%, 2.71%, and 2.86%, respectively). 16 Further more, according to the Rochester Epidemiology Project, established cardiovascular risk factors, such as male sex, current smoking, past cardiac history, family cardiac history, and dyslipidemia, are not associated with the risk of cardiovascular disease (CVD) in patients with RA, implying a substantially weaker impact (if any) than in the general population. 3, 17 For example, the magnitude of association between current smoking and CVD risk among patients with RA was 32% (statistically insignifi cant), as compared with a 219% increased risk among current smokers without RA (P = 0.008). 17 The results from another RA cohort study (n = 4,363) indicated a 20% decreased risk of cardio vascular morbidity among patients with this condition who are current smokers. 18 Furthermore, unlike the threefold increased risk of cardio vascular mortality associated with obesity in the general population, 19 obese patients with RA had a 70% decreased risk of cardio vascular mortality compared with those in the normal BMI range (the 'obesity paradox'). 20 Similarly, unlike in the general population, 21 high levels of total or lowdensity lipoprotein (LDL) cholesterol were not associated with an increased cardio vascular risk among patients with RA, whereas low levels of total or LDL cholesterol were associated with an increased risk of cardiovascular events (the 'lipid paradox'). 22 Thus, the current evidence regarding the effects of smoking, obesity, and dys lipidemia on the risk of cardiovascular events among patients with RA does not provide support for the current practice guidelines regarding cardiovascul ar risk management among these patients. 23, 24 Likewise, the smoking paradox has been observed in studies of psoriatic arthritis (PsA). Current smoking has been found to increase the risk of incident PsA by three fold in the general population, 25 but is associated with a 40% decreased risk of PsA in those with psoriasis. 4 More over, the genetic allele that is strongly associated with the risk of psoriasis (HLACw*0602) predicts a lower risk of PsA among patients with psoriasis. 26, 27 In nonrheumatic diseases Such inconsistent or paradoxical phenomena in the risk factors for sequelae events have also been observed in many nonrheumatic disease contexts (Table 2) . For example, a smoking paradox has been observed among patients who undergo isolated coronary artery bypass grafting, with current smokers having a 30% lower risk for arrhythmia than nonsmokers. 28 Similarly, among patients with a history of coronary heart disease, those who are overweight or obese (BMI ≥25) have a 20% lower risk of cardiovascularspecific mortality than indivi duals who are of normal weight (BMI <25) (the obesity paradox). 29, 30 In addition, in 2011, Canto et al. 6 showed that, among people with myo cardial infarction, wellestablished cardio vascular risk factors (such as hyper tension, smok ing, dyslipidemia, diabetes, and family history of coro nary heart disease) had protective effects on the risk of hospital mortality. Further more, in the same year, Dahabreh and Kent 31 discussed the study findings that patent foramen ovale (PFO; a type of atrial septal defect) 26, 27 Abbreviations: CVD, cardiovascular disease; OA, osteoarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.
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doubles the risk of incident cryptogenic stroke, 32 but does not increase the risk of recurrent events. 31 Another commentary comprehensively discussed a prominent neurology example of paradoxical gene effects, in which the apolipoprotein E gene was associ ated with a risk of mild cognitive impairment (the onset of Alzheimer disease), but not with the progres sion of Alzheimer disease. 33, 34 Similarly, in the field of haematology, thrombophilia increases the risk of inci dent deep vein thrombosis, but not of recurrent events (the 'thrombophilia paradox'). 35 Finally, in paedi atrics, smoking increases the risk of low birth weight, but new borns exposed to maternal smoking have been shown to have a 20% reduced risk of mortality compared with low birthweight infants not exposed to maternal smoking (the 'birth weight paradox'). 36 These apparently paradoxical phenomena have been puzzling to investigators and clinicians, as current knowl edge does not readily explain their biological mecha nisms. Nevertheless, despite these contradictory find ings that challenge conventional wisdom, clinicians con tinue to advocate consensusbased (as opposed to evidence based) recommendations. For example, patients with coronary heart disease have been advised to control their weight, cholesterol and blood pressure, and to quit smoking. 28, 37 Apart from potential differences in underlying biology, and possibly a diminished role of established risk fac tors in the presence of competing diseasespecific risk factors in index disease populations, an enticing alter native methodological explanation for these unexpected results is a type of selection bias known as index event bias. This type of bias is discussed in the next section.
Index event bias and risk factor paradox
A compelling explanation for the numerous paradoxes discussed above is index event bias (also known as col lider stratification bias), a type of selection bias. 31, 36, 38 This bias can affect research on the risk of disease sequelae when multiple risk factors for sequelae are also risk factors for having the disease in the first place. Exam ples of such research scenarios include studies of the effect of obesity on the risk of OA progression among those with OA (in which OA is considered the index event), the effect of smoking on the risk of sequelae events among those with RA (the index event), or the effect of PFO on the risk of recurrent stroke. In epidemiological terms, index event bias occurs because conditioning on the out come (that is, considering the conditional situation in which a given event, the 'outcome' , occurs)-for example, restricting the study population to those with an index event-induces dependence between these risk factors, even when they are not associated in the general popula tion (that is, the unconditioned entire population). This effect thus creates a spurious association among those risk factors with an index event. 39 As discussed in their 2011 JAMA commentary, Dahabreh and Kent demonstrated that these spurious inverse associations between PFO and other risk factors (such as age, hypertension, diabetes, and smoking) among patients with incident stroke were created by index event bias, and that such associations were not present in the general population. 31 The spurious nega tive associations between these risk factors occur because patients with PFO (a strong risk factor by itself) require less of a contribution from other risk factors to have the first stroke as compared with those without PFO. 31 Thus, among patients with incident stroke, the presence of PFO becomes inversely associated with other risk factors, including unknown or unmeasured ones that cannot be adjusted. These negative associations, particularly those with unadjusted risk factors, would bias the effect of PFO towards the null for recurrent stroke, as observed in multiple studies, because in individuals with PFO the effect of the PFO would be negatively confounded by those risk factors. 31 To help general readers understand the causal frame work and underlying logic of index event bias in graphi cal form, we have depicted an intuitive example in Figure 1 . This classic, simple experiment of a coin toss (cause) and a ringing bell (effect) demonstrates the mecha nism by which conditioning on a common effect (a 'downstream variable') induces a negative corre lation between two causes (or risk factors) that were in dependent before conditioning.
Impact on OA progression studies Index event bias could have also contributed to many null or paradoxical findings that have been observed in OA progression studies, as we have previously discussed using causal diagrams (Table 1) . 5 For example, we have depicted a typical design for an OA progression study in relation to prior obesity in Figure 2 , in which we have indicated the study population of patients with OA at study baseline (this conditioning is marked by a box around 'OA incidence' as per causal diagram conven tion [see Figure 1 and its legend for details]). In these studies, obesity (the exposure of interest) is a known cause of OA incidence and is often assessed before or at 33, 34 Abbreviations: CAD, coronary artery disease; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; PFO, patent foramen ovale; VTE, venous thrombotic embolism.
the time of OA incidence. Thus, as in the earlier PFO dis cussion, restricting the study population to patients with OA (those with an index event) introduces index event bias by creat ing a spurious negative association (marked by a dotted line) between obesity and other risk factors (includ ing unknown or unmeasured risk factors [URFs]) for OA progression (Figure 2) . 5 Heuristically, the spuri ous negative association between these risk factors occurs because patients with obesity (a strong risk fac tor by itself) require less of a contribution from other risk fac tors to develop incident OA, as compared with those who are not obese. 5 Thus, among patients already with incident OA, the presence of obesity becomes inversely associated with other risk factors, including URFs that cannot be adjusted. This spurious negative confound ing, particularly by unadjusted risk factors, would bias the effect of obesity towards the null for the risk of OA progression, as observed in previous studies. 9 Impact on RA progression studies The index event bias mechanism could also explain the inverse or null association between smoking and RA progression [14] [15] [16] (or CVD, a sequelae event of RA 3,17-18 ) among patients with RA ( Figure 3 ). Similarly to in our earlier discussion, we consider an example using risk factors that are mutually independent but are associ ated with RA incidence, namely smoking and URFs. As URFs are not associated with smoking before indivi duals develop RA, they are not confounders in a study for RA incidence (or CVD) in the general population. How ever, when studying patients with RA, smoking and these URFs are no longer independent, owing to index event bias (indicated by a dotted line linking the two factors in Figure 3 ). As smoking becomes inversely associ ated with URFs, 16 the resulting effect measure becomes under estimated or reversed (that is, paradoxical) unless the URF is appropriately adjusted for. However, not all risk factors are measured, or even known, in many obser vational studies, leading to biased effect estimates. The magnitude and direction of the bias would vary accord ing to the direction and strength of associations between smoking and URFs, and between URFs and RA progres sion (or CVD). 5, 31 Thus, index event bias can explain the apparently diminished or paradoxical role of established risk factors among those with index rheumatic condi tions (Table 1) , as well as in a number of nonrheumatic disease contexts (Table 2) . 6, 29, 30, 38 The quantitative impact of index event bias has been reported by a simulation study using numerical exam ples that was published in 2013. 40 The authors found that index event bias can be substantial, reducing the impact of a given risk factor for an incident event with a relative risk (RR) of 9.0 all the way down to a null effect for recur rent events. 40 Using the same framework, 40 we have simu lated an example that reflects a rheumatic disease context for interested readers (see Supplementary Information). In this example, when comparing the impact of a given risk factor (such as smoking) on RA incidence versus progression, an RR of 2.5 for RA incidence becomes pro tective for RA progression (RR = 0.64). These simulation data provide a numerical display for index event bias as an explanation for the smoking paradox in the risk of RA progression (or CVD sequelae) in patients with RA, as also depicted in Figure 3 .
Total effects of risk factors
Even beyond the index event bias issue discussed earlier, obtaining the total effect of a particular risk factor for a subsequent or sequelae event among individuals with index events can be challenging. As an example, we consider the total effect of smoking on the risk of CVD among patients with RA ( Figure 4) . To contrast our discussion of this issue with risk factor investigation (smoking in this case) in the general population, we have depicted the associations in a 'general' epidemiology context using a causal diagram in Figure 4a . To simp lify our discussion, we assume that smoking increases the risk of CVD through two causal pathways relevant to RA: one pathway mediated through RA (that is, smoking increases the risk of RA, which in turn increases the risk of CVD -an indirect or mediated effect), and the other through a mechanism that does not involve RA (that is, smoking increases the risk of CVD-a direct effect). In this case, the total effect of smoking on the risk of CVD is the net causal effect through both pathways. In the general When there are multiple independent causes for an effect (i.e. a common effect), conditioning on this common effect (i.e. selecting only scenarios in which the effect is observed) leads to a spurious association between those causes. A classic, simple example of a coin toss (cause) and a ringing bell (effect) can illustrate the logic behind this phenomenon. In this experiment involving two coins and a bell, the bell rings whenever either coin comes up heads on a toss of both coins. Thus, the bell ringing is a common effect of heads appearing on the toss of either coin. In causal diagrams, this is depicted as colliding causal arrows on a given common effect variable (which gives the name 'collider'). Obviously, heads appearing from one coin toss is independent of heads appearing from the other coin toss; thus, these two causes are mutually independent with a correlation coefficient between the two of 0. However, if we calculate the correlation from only the events when the bell rings (i.e. we condition on the common effect of the bell ringing), the appearances of heads on the two coins are no longer independent, resulting in a correlation coefficient of -0.5. This discrepancy occurs because if coin A came up tails, then that must mean that coin B came up heads (and vice versa), as we know that the bell rang. This simple experiment demonstrates that conditioning on a common effect induces a negative correlation between two causes or 'risk factors'. Conditioning is marked by a box around the variable name, and the spurious association is marked by a dotted line between variables, as per causal diagram convention.
population, this total effect can be estimated using con ventional confounding adjustment (indicated by the box around 'confounders' in Figure 4a ), fulfilling the primary aim of such generalpopulation studies. By contrast, in research studies that evaluate the risk factors for sequelae events among individuals with an index event, even the correction of index event bias (as discussed) might not generate an estimate of the total effect of smoking on the risk of CVD among patients with RA, which is usually the intended aim of these studies (Figure 4b ). This problem occurs because smoking status is often assessed before or at the time of RA onset, or it is mostly unchanged before and after RA onset, even if it was measured at or after the study baseline. Thus, although investigators think that they are evaluating the impact of smoking status on CVD among patients with RA, they are actually evaluating the effect of continued smoking since before the study baseline (and RA onset), reflecting the scenario depicted in Figure 3 . In the end, most of these studies estimate the direct effect of smoking (not mediated through RA) in the general population, not the total effect of smoking among patients with RA as intended. As both the direct and indirect effects of smoking on the risk of CVD are expected to occur in the same direction, one would expect the direct effect of smoking to be smaller than its total effect measured in the general population for the risk of incident CVD, which has been the case in such studies.
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Differential loss to follow-up
Classical selection bias issues are often raised in the selection of controls for case-control studies. However, cohort studies, including randomized controlled trials (RCTs), are subject to the same type of selection bias as a result of differential loss to followup.
Impact on OA progression studies
This type of selection bias has been raised in the OA research context as another potential reason underlying the null associations between obesity and OA progres sion (as determined by radiography) in several well established OA cohort studies. 5 These studies have all used serial knee radiographs at multiple followup time points to document disease progression. However, in most of these studies, a substantial proportion of sub jects were lost to followup, particularly when the time between the radiographic assessments was long. For example, the average followup time between repeated knee radio graphs in the Framingham OA study was 9 years, and of 1,473 indivi duals with knee radiographs taken at base line, 40% did not have knee radiographs at the followup visit. 44 A similar proportion of loss to followup (40%) was also reported in a UK study. 45 As obese individuals are less likely to complete followup owing to poor health, and patients whose OA has worsened are less likely to return for the last study visit owing to loss of mobility, this differential loss to followup can lead to a selection bias, 'diluting' the effect of obesity on OA progression. 5 The comparison of baseline characteristics between indivi duals who completed the followup with those who did not, a frequently used approach, does not guarantee pro tection against selection bias, as the determinants for loss to followup might not be the same between the exposed and unexposed groups, and they might even share common causes with the disease outcomes.
Impact on RA therapy studies Major loss to followup has also been observed in a series of pharmacoepidemiological studies that investigated comparative safety profiles of antiTNF DMARDs. 46, 47 Although these studies addressed the issue of confound ing (by baseline covariates) by active comparator design or propensity score analyses, they experienced consider able loss to followup during a relatively short period of time (≤1 year), which is within the range of contemporary Conditioning on (or restricting to) those with OA incidence (i.e. conditioning on a common effect, as explained in Figure 1 ) results in obesity and the URFs becoming negatively associated, as indicated by a dotted line between obesity and URFs, even though these two factors were not associated before OA incidence. This artificially-generated negative confounding results in a biased association between obesity and OA progression (represented as obesity -UR0F OA progression), leading to effect estimation biased towards the null (see Figure 1 legend for details). Abbreviations: OA, osteoarthritis; URFs, unknown or unmeasured risk factors. Figures 1 and 2 , we consider independent risk factors (specifically, smoking and URFs) that are associated with both RA and RA progression (or CVD). Note that URFs are not associated with smoking (as indicated by the absence of a line between the two factors) before individuals develop RA. Thus, URFs would not be a confounder in a study of smoking and RA progression (or CVD) in the general population. However, smoking and URFs are no longer independent (as indicated by a dotted line between them) following conditioning on a common effect (in this case, restriction of the study sample to patients with RA, as denoted by a box around RA). Consequently, a biased association occurs between smoking and RA progression (or CVD) (represented as smoking-URFs RA progression [or CVD]). As the study design leads this spurious association with URFs to operate as a negative confounder, the resulting effect measure becomes underestimated or reversed (that is, paradoxical) unless the study appropriately adjusts for URFs. Abbreviations: CVD, cardiovascular disease; RA, rheumatoid arthritis; URFs, unknown or unmeasured risk factors.
RA RCT durations. [48] [49] [50] For example, as acknowledged by its accompanying edi torial, 51 a pharmaco epidemiological study that investigated the risk of hospitalized infec tion among biologic agent users over a 1year period showed exposure retention rates of 82% in the antiTNF agent group and 60% in the nonbiologic DMARD com parison group at 60 days of followup (Figure 5a) . 46 These high and differential loss rates between groups con tinued during further followup: retention rates fell to 53% and 29%, respectively, by 180 days of followup (the study midpoint), and only 31% and 14% of participants were retained by 360 days (the end of the study) (Figure 5a ). 46 Despite effectively controlling for confounders to a level similar to that achieved in RCTs through stateoftheart methods, such a high level of differential loss to followup threatens the embedded assumption that loss to follow up is completely random (that is, not associated with an outcome, or mediators of an outcome), leaving the study design open to potential selection bias. If patients tend to discontinue TNFinhibitor treatment following a low grade infection (for example, an infection not requir ing hospitalization), the patients remaining on TNF inhibi tors would have a lower rate of hospitalized infec tion. 51 How ever, relatively insufficient efficacy of the non biologic DMARD agents could have led to glucocorticoid use, which would have contributed to both higher rates of infection and discontinuation of the corresponding drug (thus resulting in loss to followup). Unfortunately, no data are provided on the reasons for this high rate of loss to followup, 46 and it remains impossible to determine the direction or extent of this potential bias. 51 A similarly designed pharmacoepidemiology study that investigated the risk of type2 diabetes also showed a large difference in the followup rate between the anti TNF agent group and other DMARD groups 47 as depicted in Figure 5b . Interestingly, this particular study con ducted an intenttotreat (ITT) analysis (typically used in RCTs) up to a half of their followup period. Although this approach might have helped to estimate the effects of the baseline exposures without potential postbaseline confounding, 52 this method would not guard against potential selection bias owing to differen tial loss to followup. 52 Notably, the first pharmaco epidemiology study showed no increased risk of hospitalized infection associated with antiTNF agents, 46 which conflicts with the findings of a previous metaanalysis of randomized trials 53 and a recently conducted RCT published in 2013 ( Figure 5c displays the high followup retention rate of this RCT over 48 weeks). 48 We are not aware of any RCT data on the impact of biologic DMARDs on the risk of type2 dia betes to crossvalidate the results of the latter pharmacoepidemiology study. 47 Of note, a summary of the US National Research Council guidelines for missing values (including loss to followup rates) stated the fol lowing as part of their key findings: "Substantial instances of missing data are a serious problem that undermines the scientific credibi lity of causal conclusions from clinical trials. The assumption that analysis methods can compensate for such missing data are not justified, so aspects of trial design that limit the likelihood of missing data should be an important objective." 54 This conclu sion emphasizes the importance of minimizing loss to followup in design and execution of clinical trials, as well as the associated difficulties of dealing with missing data at the analysis phase. 54 Furthermore, in an editorial published in 2013, Hernan and colleagues outlined the limitations of the widely popular ITT approach, even in randomized trials (particularly for safety trials), and sug gested advanced methods to overcome these limitations. 52 These principles should also be applicable to observa tional studies, as they are clearly not immune to this type of bias; if anything, observational studies ought to be subject to a higher level of scrutiny for any type of bias.
Depletion of susceptibles
Differential depletion of susceptible participants can bias effect estimates of hazardous exposures towards the null or in a protective direction owing to attrition of study participants based on their susceptibility to the expo sure. A classical example is the agestratified effects of smoking on coronary heart disease mortality in the British Physician's study (n = 34,439). 55 With ageing, participants who were susceptible to coronary heart dis ease (particularly that related to smoking) tended to die of smokingrelated causes, and only those who were *Theoretically, smoking initiation after RA onset would be equivalent to smoking exposure in the general population in part a; however, in practice, this would be unusual after RA onset. Alternatively, the impact of smoking cessation can be evaluated in these studies. Abbreviations: CVD, cardiovascular disease; RA, rheumatoid arthritis.
less susceptible remained. Thus, both the RRs and the risk differences for coronary heart disease in that study showed a graded decline with ageing from the youngest age category (35-44 years), and smoking became protec tive in the oldest category of 75-84 years (RRs 5.7 and 0.9, respectively). 55 Similar phenomena have been observed in rheuma tic disease contexts. For example, downward trends in the associations between obesity and mortality among patients with RA have been reported, ranging from an RR of 1.6 (positive) for those <50 years of age to 0.9 (nega tive) for those >70 years of age. 56 A simple methodo logical explanation is that those who were most susceptible to obesityrelated complications died before the age at which they would have been eligible for study enrolment. 57 Further more, the same differential depletion of suscepti ble individuals between compared groups can explain the decreasing RR of complications (such as venous throm botic embolism) in inflammatory rheumatic conditions over time following the onset of the underlying inflam matory conditions. 58, 59 This phe nomenon highlights the superiority of using incident exposures (as opposed to prevalent exposures), particularly in a setting in which the induction time (the time between RA onset and the incidence of venous thrombotic embolism) is short. Nevertheless, when the induction time associated with chronic exposures is relatively long (for example, in the case of the impact of smoking on the risk of lung cancer), this selection bias manifests after the peak effect age of the exposure, thus primarily among elderly individuals, as described earlier. 55, 57 The most notable example is that of the impact of hormonal replacement therapy (HRT) on CVD among postmenopausal women. Prominent observational studies that investigated the effects of a mixture of both prevalent and incident use of HRT have shown a 40-50% protective effect against the risk of myocardial infarc tion. 60, 61 However, a large subsequent RCT (the Women's Health Initiative [n = 16,608]) showed hazardous effects, particularly during the early stages of HRT use. 62 When the same previous observational study was analysed by emulating an RCT study design (using incident expo sure of HRT and an ITTequivalent approach), the results converged with those of the RCT. 63 The lesson remains that selection bias can be ubiquitous and could, therefore, potentially lead the field astray. 46, 47 showed high and differential loss rates between groups. c | By contrast, much lower levels of loss to follow-up were observed in a randomized trial 46 of a biologic agent in RA at similar time points. Despite effectively controlling for confounders in the observational studies, 46, 47 such a high level of differential loss to follow-up threatens the embedded assumption that loss to follow-up is completely random (i.e. not associated with an outcome, or mediators of an outcome), leaving the study design open to potential selection bias. Abbreviation: RA, rheumatoid arthritis.
Immortal time bias
Immortal time bias occurs owing to periods of follow up time that are protected from deaths or end points by virtue of the study design. 64 Such bias can either lead to misclassification bias through the incorrect classification of unexposed 'immortal time' (before initial exposure) as part of the followup period of the exposed group or result in selection bias when periods of immortal time are differentially excluded from the analysis. 64 Both types of bias lead to a downward bias of effect estimates (that is, towards the null or in a protective direction). This dif ferential exclusion can occur from the use of a hierarchi cal approach to determination of treatment status or a predetermined prescription pattern of compared treat ment options in the study population. 64 For example, in a study of the potential survival impact of biologic agents in patients with RA (compared with nonbiologic agents), the start of followup (defined as the date of the first use of the biologic agent or nonbiologic therapy) would come considerably later following RA diagnosis for bio logic agent users than for nonbiologic agent users (the comparator), because a large proportion of biologic agent users (if not all, as in some countries or regions) had been previously treated with nonbiologic agents (and survived these previous treatments) ( Figure 6 ). Thus, unless the excluded period of nonbiologic agent use before biologic agent use (the unexposed immortal time) is appropriately assigned to the nonbiologic treatment group in a time varying manner, 64 the immortal timeinduced selection bias could lead to a major survival advantage for biologic agent users.
Conclusions
Unbiased research that accurately determines modifi able risk factors for the development of rheumatic and musculo skeletal conditions and their sequelae is critical to reduce their disease burden. As reviewed here, the evi dence on risk factors for disease sequelae among patients with rheumatic diseases has been inconsistent or para doxical, unlike the research findings on risk factors for incident conditions. Beyond potential biological explana tions for these counterintuitive findings, an enticing methodological explanation could be a type of selection bias known as index event bias, which can affect research on disease sequelae (as shown in many nonrheumatic conditions). Furthermore, mismatches between the study question of interest and study design could have led to the many apparent paradoxes in the field because many of these studies have not investigated the total impact of those risk factors that occur after the index events. Many powerful confounding control methods (such as propen sity score methods or active comparator analysis) have been effective in pharmacoepidemiological research in rheumatic conditions; however, they do not address selection bias caused by potential differential loss to followup. Depletion of susceptibles (another type of selection bias) can explain the decreasing impact of risk factors on mortality with ageing in many rheumatic con ditions, including RA, and the null (or inverse) associa tions of prevalent exposure studies. Immortal time bias as a form of selection bias (as opposed to as a type of mis classification bias) can also create strong spurious inverse associations (for example, resulting in an apparent highly protective effect of a particular drug).
The key lesson from these experiences is that selection bias can be ubiquitous, and holds the potential to mislead the field. Therefore, researchers and clinicians should pay attention to this issue in all phases of research, including its design, execution and interpretation. Several practical measures can be taken. First, when planning a research study, a wellformed and testable hypothesis should be developed that considers potential selection bias issues (at least to the same extent as confounding and measure ment bias issues) from the start. Study design tends to be more important than analytical choices in avoiding selection bias, and involving methodologists with rele vant expertise from the beginning of the study design process can help greatly to avoid these biases. Second, the speci fic intent of the research question and its corres pond ing effect measures (for example, total, direct, or indirect effects) should be clearly determined to avoid mis matches between the two. We find constructing plausible causal diagrams (as in Figures 1-4) to be helpful, particularly in facilitating explicit display and discussion of causal questions and the potential role of involved variables. Third, an appropriate study design and analytical method should be used to fit the specific research question that was intended. This measure is crucial when assessing the direct and mediated effects of risk factors, as potential selection bias (for example, index event bias) is likely to occur. Fourth, in general, use of incident exposure (as opposed to prevalent exposure) helps to avoid depletion of susceptibles, particularly if outcomes occur early after the initiation of exposure and cumulative exposure is less relevant (although chronic exposures, such as obesity and smoking, are less or not subject to these recommenda tions). This approach further helps to avoid selection bias by ensuring that the exposure precedes the occurrence of any mediators and the outcome, and that any con founders precede the occurrence of the exposure. Fifth, more studies about the natural history of rheumatic conditions and their sequelae are needed to clarify the time sequence of relevant biological stages and to avoid adjusting for causal mediators. With such knowledge often incomplete or unavailable, investigators are encouraged to perform sensitivity analyses under various causal assumptions, to assess the impact of such assumptions on their results. Finally, more methodo logical research on selection bias issues specifically in rheumatic conditions would help to refine these recommendations towards more comprehen sive and practical guidelines, as well as help investigators avoid the pitfalls posed by this crucial type of bias and ensure the validity of future rheumatology research.
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A search for original articles published between 1965 and 2013 and focusing on the risk factors for key rheumatic conditions as well as those for their sequela conditions was performed in MEDLINE and PubMed. The search terms included "osteoarthritis", "rheumatoid arthritis", "psoriasis", "psoriatic arthritis", "risk factors", "smoking", "obesity", "gene", "genetic", "loci", "progression", "myocardial infarction", "cardiovascular outcomes", and "death" alone and in combination. A few selected key reviews and seminal papers were also included. Papers cited in this Review were selected according to their relevance to the subject.
